Genzyme and Icahn agree compromise deal
June 10, 2010Research and Development, Sales and Marketing Genzyme
Carl Icahn has won his battle with Genzyme to have his associates given a place on the company’s board.The US …
Study re-opens debate about pharma chemicals in wastewater
June 10, 2010Manufacturing and Production manufacturing, manufacturing compliance
Wastewater from pharmaceutical manufacturing facilities is a major source of drug compounds in the environment, according to a new study …
Digital Pharma: Online clinical collaboration
June 10, 2010Research and Development biomarkers, digital doctors, digital pharma research, proteomic
A new online educational resource will offer researchers across the medical community access to peer-reviewed information on biomarkers. The portal …
NICE rejects GSK’s Revolade
June 10, 2010Sales and Marketing ITP, NICE, Revolade
NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …
Pfizer appoints neuroscience research head
June 10, 2010Research and Development Pfizer, appointment, research and development
Pfizer has appointed Dr Michael Ehlers chief scientific officer for neuroscience research. Dr Ehlers most recently served as the George …
NICE says no to GSK breast cancer drug
June 10, 2010Sales and Marketing NICE, Tyverb
NICE has issued final draft guidance restricting use of GlaxoSmithKline’s breast cancer drug Tyverb to clinical trials, citing high cost …
‘Stellar’ performance from targeted lung cancer drug
June 9, 2010Research and Development Pfizer, biomarkers, crizotinib
A new targeted treatment for non small cell lung cancer has produced spectacular results in a sub-group of patients. Pfizer’s …
Nerve gas antidote completes phase I trial
June 9, 2010Research and Development Protalix, biodefence
Israeli biotech firm Protalix has completed a phase I clinical trial for its intravenous nerve gas antidote. The drug is …
Eisai’s breast cancer drug impresses at ASCO
June 9, 2010Research and Development ASCO, Eisai, Xeloda, eribulin
A new cancer drug developed by Japanese pharma company Eisai has shown promise in increasing overall survival rates in heavily …
Lansley calls for “cultural shift in the NHS”
June 9, 2010NHS, government, king's fund
In his first speech as health secretary Andrew Lansley has called for a “cultural shift in the NHS”, moving away …
Tim Wragg to head up Millward Brown in Europe
June 9, 2010Medical Communications Millward Brown, appointment, medical communications
Research company Millward Brown has appointed Tim Wragg to the newly-created position of chief executive, Europe. In his new position …
Dr Laurent Audoly joins Pieris
June 9, 2010Research and Development Pieris, appointment, research and development
French biotech company Pieris has appointed Dr Laurent Audoly as chief scientific officer. Dr Audoly was most recently biologics research …
Talking Point: Crisis Management
June 9, 2010Medical Communications Red Door, Talking Point
It is surprising to me how many companies and people in business are under-prepared and under-rehearsed for a crisis. On …
EMA sees fewer quality defects in ’09 inspections
June 9, 2010Manufacturing and Production API, EMA, manufacturing, manufacturing compliance
The European Medicines Agency carried out 175 inspections of manufacturing facilities in 2009, a little lower than its target, according …
Eurocom expands international network
June 9, 2010Medical Communications Eurocom, PBK
Eurocom Healthcare Communications has expanded its international communications network, adding leading Austrian agency PBK Ideennrerich to the fold. Eurocom said …
Merck Serono resubmits oral MS therapy to FDA
June 8, 2010Research and Development Cladribine, MS, Merck KGaA
Merck Serono has re-submitted its oral multiple sclerosis therapy cladribine to US regulators. Merck Serono, a Swiss division of Merck …
Sanofi to develop monoclonal antibody jabs
June 8, 2010Research and Development Sanofi Pasteur, Vivalis, vaccines
Sanofi-Aventis is to develop a range of monoclonal antibody for use against infectious diseases. The French pharma company’s vaccines arm …
EU regulators to assess potential lupus breakthrough drug
June 8, 2010Sales and Marketing Benlysta, Human Genome Sciences, Lupus
GlaxoSmithKline and Human Genome Sciences have submitted a marketing application to the European Medicines Agency for their new lupus drug. …
CME Spotlight: Power to the people
June 8, 2010Medical Communications, Sales and Marketing CME Spotlight, transparency
The UK general election is now over and as we stayed up to watch the count, or woke on the …
EMA under fire for blocking data access
June 8, 2010Research and Development, Sales and Marketing Acomplia, Alli, EMA, Xenical, data
The European ombudsman has called for the European Medicines Agency to grant access to clinical study reports and trial protocols …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
